Skip to content Skip to footer
Subscribe Now

NEWS

Avricore Health’s HealthTab Enters Multi-Year Collaboration with Abbott to Expand Point-of-Care Testing Across the UK
Shots: Avricore Health’s HealthTab entered a multi-year collaboration agreement with Abbott to supply and distribute Abbott’s point-of-care testing products through the HealthTab platform across the UK, supporting the expansion of pharmacy-based testing. Under the agreement, HealthTab will distribute Abbott’s Afinion 2 Analyzer through NHS-linked pharmacies for HbA1c and lipid profile testing, while establishing a framework…
August 20, 2026
Amplitude Therapeutics and Eli Lilly Partner to Develop Trans-Amplifying RNA Vaccines for Infectious Diseases
Shots: Amplitude and Lilly entered into a strategic research collaboration and licensing agreement to discover and develop trans-amplifying RNA (taRNA) vaccine candidates for infectious diseases. Lilly retains the option to add up to two additional infectious disease targets. The collaboration combines Amplitude’s proprietary taRNA platform with Lilly’s global development, manufacturing, regulatory, and commercialisation capabilities. Amplitude…
August 20, 2026
Lupin and Tenpoint Therapeutics Partner to Commercialize YUVEZZI in Key European Markets for Presbyopia
Shots: Lupin, through its wholly owned subsidiary VISUfarma B.V., entered into an exclusive licensing agreement with Visus Therapeutics, a wholly owned subsidiary of Tenpoint Therapeutics, to commercialize YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for presbyopia in the European Union, United Kingdom, Switzerland, Norway, and Iceland Under the agreement, VISUfarma will hold exclusive rights…
August 20, 2026
Tolerance Bio Licenses Efineptakin Alfa from NeoImmuneTech to Advance Thymic Function and Immune Resilience Programs
Shots: Tolerance Bio entered into an exclusive license agreement with NeoImmuneTech for the development and commercialization of efineptakin alfa (NT-I7), for certain thymus-related indications in the Americas and Europe. The company also plans to initiate P-II studies evaluating the therapy for enhancement of thymic function Under the agreement, Tolerance Bio will advance efineptakin alfa alongside…
August 20, 2026
Ultragenyx Receives FDA Accelerated Approval for GENGLYCOS Gene Therapy to Treat the Underlying Cause of GSDIa
Shots: Ultragenyx reported the US FDA accelerated approval to GENGLYCOS (pariglasgene brecaparvovec-opnr; DTX401) for adults and pediatric patients (≥8yrs., n=46) with glycogen storage disease type Ia (GSDIa) The approval was supported by the P-III (GlucoGene) study, in which GENGLYCOS (n=20) demonstrated a statistically significant reduction in cornstarch requirements at 48wks. vs PBO (n=24) (p<0.001). The…
August 20, 2026
NORROY BIOSCIENCE Receives FDA Breakthrough Therapy and Fast Track Designations for 68Ga-NYM096 in Kidney Cancer Imaging
Shots: NORROY BIOSCIENCE reported that the FDA has granted Breakthrough Therapy and FTD to 68Ga-NYM096, a radiopharmaceutical imaging agent targeting CAIX for PET imaging of clear cell renal cell carcinoma (ccRCC) 68Ga-NYM096 is being developed as a non-invasive PET imaging agent to characterize indeterminate renal masses identified by CT or MRI and help differentiate ccRCC…
August 20, 2026
DeepCyte Launches AI Toxicology Atlas to Predict Drug Safety Risks
Shots: DeepCyte has launched DeeTox Atlas, the first single-cell metabolomic reference atlas for drug toxicity mechanisms, with enterprise pilots set to begin soon & three of the top 20 pharma companies already in pilot discussions Platform is built from 2 independent studies covering ~100 toxicant compounds, 300k cells & ~500 metabolites/cell, generating 3,000+ single-cell measurements…
August 19, 2026
Merck and Moderna Report the INTerpath-001 Trial Data on Intismeran Autogene + Keytruda for Completely Resected Stage IIB-IV Melanoma
Shots: Merck & Moderna have reported the P-III (INTerpath-001) trial data assessing adj. intismeran autogene (1mg, Q3W for 9 doses) + Keytruda (400mg, Q6W up to 9 cycles) vs Keytruda alone in 1,137 pts with high-risk (stage IIB-IV) resected cutaneous melanoma Intismeran plus Keytruda as adj. therapy showed improvements in RFS (1EP) and DMFS (2EP)…
August 19, 2026
ivWatch Seeks 510(k) Clearance for its SmartTouch+ Sensor to Expand Continuous IV Monitoring to White-Opaque Infusates
Shots: The US FDA has received a 510(k) application for the SmartTouch+ Sensor to detect infiltration & extravasation events associated with both clear and white-opaque fluids early The SmartTouch+ Sensor expands ivWatch’s monitoring to lipid-based fluids like TPN & propofol, with the Patient Monitor performing 18,000+ checks/hour to detect infiltration or extravasation & alert clinicians,…
August 19, 2026
VectorBuilder and Lir Therapeutics Partner to Develop AAV Capsids
Shots: VectorBuilder & Lir have collaborated to develop AAV capsids, leveraging VectorBuilder’s DeepCap platform & expertise & Lir’s nAAVigator AI platform Lir will use its platform & lab-in-the-loop workflow to enhance capsids discovered through DeepCap, targeting higher productivity, full-capsid yield, quality, robustness, lower doses, & greater tissue specificity with reduced off-target delivery & immune recognition …
August 19, 2026
Load more